Evidence map›Paper›PMID 32226684›Full record

ArticleCureus2020

Efficacy and Tolerability of Ashwagandha Root Extract in the Elderly for Improvement of General Well-being and Sleep: A Prospective, Randomized, Double-blind, Placebo-controlled Study.

Sunil B Kelgane, Jaysing Salve, Prasanthi Sampara, Khokan Debnath

Open access · diamondAbstract read
In one paragraph

Article in Cureus, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
5.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Safety and tolerability of Ashwagandha (Frontiers in nutrition · 2026
    Trial
  4. Trial
  5. Trial
  6. Trial
  7. Observational
  8. Nutraceutical Applications ofFoods (Basel, Switzerland) · 2026
    Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Biopsychological Effects of Ashwagandha (Muscles (Basel, Switzerland) · 2025
    Review
  14. Ashwagandha (Nutrients · 2025
    Review
  15. Review
  16. Article
  17. Emerging Vistas for the NutraceuticalPharmaceuticals (Basel, Switzerland) · 2024
    Review
  18. Sub-acute toxicity of Ashwagandha (Toxicology reports · 2023
    Article
  19. AshwagandhaPharmaceutics · 2023
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 2 countries.

Sunil B KelganeEmergency Medical Services, Maharashtra Emergency Medical Services, Pune, IND.
Jaysing SalveInternal Medicine, Risk Care Hospital, Thane, IND.
Prasanthi SamparaSMART Research, Sunshine Hospitals, Hyderabad, IND.
Khokan DebnathFamily Medicine, Prakruti Hospital, Mumbai, IND.
B. J. Medical College & Sassoon Hospital · INIndravati Hospital & Research Centre · INRisk Engineering (Bulgaria) · BGSunshine Hospitals · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background Ashwagandha is an excellent adaptogen that is being used since ancient times in Ayurvedic medicine. Traditionally, it is used for various ailments and general well-being, including the treatment of geriatric patients. Managing quality of life (QoL) remains a challenge for the elderly population, especially joint pain management, sleep, and general well-being. With a growing global elderly population, QoL management with efficient medication and supplementation is the major healthcare requirement. Objective The objective of this study was to assess the safety, efficacy, and tolerability of Ashwagandha (

Indexed as

agingashwagandhaelderlymental alertnessquality of lifesleep quality

Identifiers

PMID32226684
PMCPMC7096075
OpenAlexW3008402312

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.